Abstract
Gram negative sepsis remains a high cause of mortality and places a great burden on public health finance in both the developed and developing world. Treatment of sepsis, using antibiotics, is often ineffective since pathology associated with the disease occurs due to dysregulation of the immune system (failure to return to steady state conditions) which continues after the bacteria, which induced the immune response, have been cleared. Immune modulation is therefore a rational approach to the treatment of sepsis but to date no drug has been developed which is highly effective, cheap and completely safe to use. One potential therapeutic agent is VIP, which is a natural peptide and is highly homologous in all vertebrates. In this review we will discuss the effect of VIP on components of the immune system, relevant to gram negative sepsis, and present data from animal models. Furthermore we will hypothesise on how these studies could be improved in future and speculate on the possible different ways in which VIP could be used in clinical medicine.
Keywords: Cytokine, inflammation, Sepsis, transcription bacteria, VIP, Systemic inflammatory response syndrome (SIRS), pathogen-associated molecular patterns (PAMPs), Toll-like receptor (TLR), cardiovascular collapse, dysregulated cytokine production, Pathogen Recognition, Therapeutic targets.
Endocrine, Metabolic & Immune Disorders - Drug Targets
Title:VIP as a Potential Therapeutic Agent in Gram Negative Sepsis
Volume: 12 Issue: 4
Author(s): Hiba Ibrahim, Paul Barrow and Neil Foster
Affiliation:
Keywords: Cytokine, inflammation, Sepsis, transcription bacteria, VIP, Systemic inflammatory response syndrome (SIRS), pathogen-associated molecular patterns (PAMPs), Toll-like receptor (TLR), cardiovascular collapse, dysregulated cytokine production, Pathogen Recognition, Therapeutic targets.
Abstract: Gram negative sepsis remains a high cause of mortality and places a great burden on public health finance in both the developed and developing world. Treatment of sepsis, using antibiotics, is often ineffective since pathology associated with the disease occurs due to dysregulation of the immune system (failure to return to steady state conditions) which continues after the bacteria, which induced the immune response, have been cleared. Immune modulation is therefore a rational approach to the treatment of sepsis but to date no drug has been developed which is highly effective, cheap and completely safe to use. One potential therapeutic agent is VIP, which is a natural peptide and is highly homologous in all vertebrates. In this review we will discuss the effect of VIP on components of the immune system, relevant to gram negative sepsis, and present data from animal models. Furthermore we will hypothesise on how these studies could be improved in future and speculate on the possible different ways in which VIP could be used in clinical medicine.
Export Options
About this article
Cite this article as:
Ibrahim Hiba, Barrow Paul and Foster Neil, VIP as a Potential Therapeutic Agent in Gram Negative Sepsis, Endocrine, Metabolic & Immune Disorders - Drug Targets 2012; 12 (4) . https://dx.doi.org/10.2174/187153012803832611
DOI https://dx.doi.org/10.2174/187153012803832611 |
Print ISSN 1871-5303 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3873 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Acute Severe Arterial Hypertension: Therapeutic Options
Current Drug Targets Extracellular Proteases as Targets for Drug Development
Current Protein & Peptide Science Emerging Vascular Risk Factors in Women: Any Differences from Men?
Current Medicinal Chemistry Use of Cocktail Probe Drugs for Indexing Cytochrome P450 Enzymes in Clinical Pharmacology Studies – Review of Case Studies
Drug Metabolism Letters ESVS Guidelines: Section A - Prevention in Patients with Carotid Stenosis
Current Vascular Pharmacology New Therapeutic Applications of Phosphodiesterase 5 Inhibitors (PDE5-Is)
Current Medicinal Chemistry Interplay between RNA Methylation Eraser <i>FTO</i> and Writer <i>METTL3</i> in Renal Clear Cell Carcinoma Patient Survival
Recent Patents on Anti-Cancer Drug Discovery Children with Chronic Kidney Disease and Hypertension: Could Hypertension Footprints be Early Biomarkers?
Current Hypertension Reviews Nutrigenomics and Its Approaches for Control of Chronic Diseases
Current Biotechnology Fluoroquinolones: Blessings Or Curses
Current Drug Targets Cardiovascular Pharmacogenetics of Anti-Thrombotic Agents and Non-Steroidal Anti-Inflammatory Drugs
Current Molecular Medicine Pain Management in Hematological Patients with Major Organ Dysfunctions and Comorbid Illnesses
Cardiovascular & Hematological Agents in Medicinal Chemistry Apoptogenic Signal Transduction in Arteriosclerosis-Associated Cells – Opportunities for Future Therapy?
Vascular Disease Prevention (Discontinued) Transient Receptor Potential Channels, the Kidney and Hypertension
Current Hypertension Reviews Anti-platelet Drug-loaded Targeted Technologies for the Effective Treatment of Atherothrombosis
Current Drug Targets Antioxidant Treatment and Endothelial Dysfunction: Is it Time for Flavonoids?
Recent Patents on Cardiovascular Drug Discovery Regulation of HIF-1α at the Transcriptional Level
Current Pharmaceutical Design Cyclooxygenase Inhibitors: Instrumental Drugs to Understand Cardiovascular Homeostasis and Arterial Thrombosis
Cardiovascular & Hematological Disorders-Drug Targets Nebulizable Cycloserine Loaded PLGA Nanoparticles: Formulation Design, in vitro Evaluation and Stability Studies
Current Nanomedicine Neuropeptide/Receptor Expression and Plasticity in Micturition Pathways
Current Pharmaceutical Design